# Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Source: https://onco.cc/trials/nct05565417/  
OnCo record `nct05565417` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fruquintinib in non-small-cell lung cancer and small-cell lung cancer, run by Immunitas Therapeutics, active and no longer recruiting.

## Summary

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05565417 by Immunitas Therapeutics, with 67 participants enrolled, started 2022-11-28 and due to reach its primary completion in 2026-01. Interventions recorded: IMT-009, Fruquintinib. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05565417
- Phase: 1/2
- Setting: A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
- Sponsor: Immunitas Therapeutics
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT05565417: https://clinicaltrials.gov/study/NCT05565417

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05565417.json